Erlotinib hydrochloride (Tarceva®) is a member of a class of small molecule inhibitors that
targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti …

Background: To determine the efficacy and safety of anti-angiogenic drugs combined with
erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC), we performed a …

Methods An open labeled, expanded access program (EAP) was conducted on 44
pathologically confirmed advanced NSCLC patients who had received at least one regimen …

Introduction Little data is available on patients with advanced non-squamous NSCLC
treated with erlotinib specifically after failure of first-line pemetrexed-containing …

Background Several studies of EGFR TKIs have shown a benefit in response and
progression-free survival (PFS) for NSCLC patients harboring EGFR mutations in the first …

Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …

PURPOSE: Erlotinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) which has demonstrated a survival benefit in non-small-cell lung cancer …

Objective Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a
significant improvement of survival in non-small-cell lung cancer (NSCLC) after the failure of …

8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …